Nabriva Therapeutics GAAP EPS of -$4.21 misses by $0.18, revenue of $9.15M misses by $1.53M

Stock Information for Nabriva Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nabriva Therapeutics plc

Arbutus Appoints Two New Executives
Nabriva Therapeutics Provides Corporate Update
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.